Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab. J of Skin [Internet]. 2017 Oct. 27 [cited 2025 Oct. 6];1(3.1):s5. Available from: https://skin.dermsquared.com/skin/article/view/77